vs
BIODESIX INC（BDSX）与RadNet, Inc.（RDNT）财务数据对比。点击上方公司名可切换其他公司
RadNet, Inc.的季度营收约是BIODESIX INC的19.0倍（$547.7M vs $28.8M）。RadNet, Inc.净利率更高（-0.1% vs -13.8%，领先13.7%）。BIODESIX INC同比增速更快（40.8% vs 14.8%）。过去两年BIODESIX INC的营收复合增速更高（39.3% vs 12.6%）
BIODESIX INC是一家专注于肿瘤与感染病领域的分子诊断企业，开发并商业化创新血液检测解决方案，主要服务北美地区的医疗机构、生物制药合作伙伴及患者，核心业务包括辅助临床决策的个性化医疗产品。
RadNet是美国领先的放射医疗服务企业，总部位于加利福尼亚州洛杉矶，是美国规模最大的独立固定地址诊断影像中心运营商，按网点数量及年度影像业务收入计均居行业首位。截至2025年，该公司在全美8个州持有或运营超400家影像中心，提供门诊诊断影像服务。
BDSX vs RDNT — 直观对比
营收规模更大
RDNT
是对方的19.0倍
$28.8M
营收增速更快
BDSX
高出26.0%
14.8%
净利率更高
RDNT
高出13.7%
-13.8%
两年增速更快
BDSX
近两年复合增速
12.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $28.8M | $547.7M |
| 净利润 | $-4.0M | $-597.0K |
| 毛利率 | — | — |
| 营业利润率 | -6.8% | 5.1% |
| 净利率 | -13.8% | -0.1% |
| 营收同比 | 40.8% | 14.8% |
| 净利润同比 | 51.8% | -111.2% |
| 每股收益（稀释后） | $-3.35 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDSXRDNT
| Q4 25 | $28.8M | $547.7M | ||
| Q3 25 | $21.8M | $522.9M | ||
| Q2 25 | $20.0M | $498.2M | ||
| Q1 25 | $18.0M | $471.4M | ||
| Q4 24 | $20.4M | $477.1M | ||
| Q3 24 | $18.2M | $461.1M | ||
| Q2 24 | $17.9M | $459.7M | ||
| Q1 24 | $14.8M | $431.7M |
净利润BDSXRDNT
| Q4 25 | $-4.0M | $-597.0K | ||
| Q3 25 | $-8.7M | $5.4M | ||
| Q2 25 | $-11.5M | $14.5M | ||
| Q1 25 | $-11.1M | $-37.9M | ||
| Q4 24 | $-8.3M | $5.3M | ||
| Q3 24 | $-10.3M | $3.2M | ||
| Q2 24 | $-10.8M | $-3.0M | ||
| Q1 24 | $-13.6M | $-2.8M |
营业利润率BDSXRDNT
| Q4 25 | -6.8% | 5.1% | ||
| Q3 25 | -32.4% | 5.2% | ||
| Q2 25 | -48.6% | 6.2% | ||
| Q1 25 | -50.9% | -5.1% | ||
| Q4 24 | -32.5% | 5.1% | ||
| Q3 24 | -47.3% | 7.4% | ||
| Q2 24 | -46.0% | 7.6% | ||
| Q1 24 | -74.4% | 2.6% |
净利率BDSXRDNT
| Q4 25 | -13.8% | -0.1% | ||
| Q3 25 | -40.0% | 1.0% | ||
| Q2 25 | -57.3% | 2.9% | ||
| Q1 25 | -61.8% | -8.0% | ||
| Q4 24 | -40.4% | 1.1% | ||
| Q3 24 | -56.5% | 0.7% | ||
| Q2 24 | -60.3% | -0.6% | ||
| Q1 24 | -91.9% | -0.6% |
每股收益（稀释后）BDSXRDNT
| Q4 25 | $-3.35 | $0.00 | ||
| Q3 25 | $-1.16 | $0.07 | ||
| Q2 25 | $-0.08 | $0.19 | ||
| Q1 25 | $-0.08 | $-0.51 | ||
| Q4 24 | $-5.02 | $0.08 | ||
| Q3 24 | $-1.40 | $0.04 | ||
| Q2 24 | $-0.08 | $-0.04 | ||
| Q1 24 | $-0.14 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.0M | $767.2M |
| 总债务越低越好 | $50.0M | $1.1B |
| 股东权益账面价值 | $-2.5M | $1.1B |
| 总资产 | $87.5M | $3.8B |
| 负债/权益比越低杠杆越低 | — | 1.00× |
8季度趋势，按日历期对齐
现金及短期投资BDSXRDNT
| Q4 25 | $19.0M | $767.2M | ||
| Q3 25 | $16.6M | $804.7M | ||
| Q2 25 | $20.7M | $833.2M | ||
| Q1 25 | $17.6M | $717.3M | ||
| Q4 24 | $26.2M | $740.0M | ||
| Q3 24 | $31.4M | $748.9M | ||
| Q2 24 | $42.2M | $741.7M | ||
| Q1 24 | $11.5M | $527.0M |
总债务BDSXRDNT
| Q4 25 | $50.0M | $1.1B | ||
| Q3 25 | $50.0M | $1.1B | ||
| Q2 25 | $50.0M | $1.1B | ||
| Q1 25 | $40.0M | $1.0B | ||
| Q4 24 | $40.0M | $1.0B | ||
| Q3 24 | $40.0M | $1.0B | ||
| Q2 24 | $40.1M | $1.0B | ||
| Q1 24 | $40.1M | $834.6M |
股东权益BDSXRDNT
| Q4 25 | $-2.5M | $1.1B | ||
| Q3 25 | $-1.7M | $1.1B | ||
| Q2 25 | $1.1M | $932.3M | ||
| Q1 25 | $11.1M | $898.1M | ||
| Q4 24 | $20.9M | $902.3M | ||
| Q3 24 | $27.9M | $895.3M | ||
| Q2 24 | $36.3M | $881.0M | ||
| Q1 24 | $-5.5M | $873.0M |
总资产BDSXRDNT
| Q4 25 | $87.5M | $3.8B | ||
| Q3 25 | $88.7M | $3.7B | ||
| Q2 25 | $87.7M | $3.5B | ||
| Q1 25 | $86.2M | $3.3B | ||
| Q4 24 | $97.2M | $3.3B | ||
| Q3 24 | $102.7M | $3.3B | ||
| Q2 24 | $115.8M | $3.2B | ||
| Q1 24 | $87.2M | $3.0B |
负债/权益比BDSXRDNT
| Q4 25 | — | 1.00× | ||
| Q3 25 | — | 1.04× | ||
| Q2 25 | 43.95× | 1.18× | ||
| Q1 25 | 3.62× | 1.12× | ||
| Q4 24 | 1.92× | 1.13× | ||
| Q3 24 | 1.44× | 1.14× | ||
| Q2 24 | 1.10× | 1.17× | ||
| Q1 24 | — | 0.96× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $778.0K | $84.2M |
| 自由现金流经营现金流 - 资本支出 | $692.0K | — |
| 自由现金流率自由现金流/营收 | 2.4% | — |
| 资本支出强度资本支出/营收 | 0.3% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-23.5M | — |
8季度趋势，按日历期对齐
经营现金流BDSXRDNT
| Q4 25 | $778.0K | $84.2M | ||
| Q3 25 | $-8.9M | $52.8M | ||
| Q2 25 | $-6.6M | $120.3M | ||
| Q1 25 | $-8.6M | $41.5M | ||
| Q4 24 | $-4.1M | $42.5M | ||
| Q3 24 | $-10.7M | $57.4M | ||
| Q2 24 | $-18.6M | $116.0M | ||
| Q1 24 | $-15.3M | $17.1M |
自由现金流BDSXRDNT
| Q4 25 | $692.0K | — | ||
| Q3 25 | $-8.9M | — | ||
| Q2 25 | $-6.6M | — | ||
| Q1 25 | $-8.7M | — | ||
| Q4 24 | $-4.9M | — | ||
| Q3 24 | $-10.9M | — | ||
| Q2 24 | $-20.5M | — | ||
| Q1 24 | $-15.5M | — |
自由现金流率BDSXRDNT
| Q4 25 | 2.4% | — | ||
| Q3 25 | -41.0% | — | ||
| Q2 25 | -33.1% | — | ||
| Q1 25 | -48.3% | — | ||
| Q4 24 | -24.2% | — | ||
| Q3 24 | -60.1% | — | ||
| Q2 24 | -114.3% | — | ||
| Q1 24 | -104.9% | — |
资本支出强度BDSXRDNT
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 0.4% | — | ||
| Q4 24 | 4.1% | — | ||
| Q3 24 | 1.3% | — | ||
| Q2 24 | 10.7% | — | ||
| Q1 24 | 1.6% | — |
现金转化率BDSXRDNT
| Q4 25 | — | — | ||
| Q3 25 | — | 9.75× | ||
| Q2 25 | — | 8.33× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 7.96× | ||
| Q3 24 | — | 17.89× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDSX
| Diagnostic Tests | $25.1M | 87% |
| Development Services | $3.6M | 13% |
RDNT
| Commercial Insurance1 | $301.0M | 55% |
| Medicare1 | $129.2M | 24% |
| Capitation Arrangements | $31.9M | 6% |
| Health Care Other | $20.4M | 4% |
| Digital Health | $16.4M | 3% |
| Other | $15.2M | 3% |
| Medicaid1 | $14.0M | 3% |
| Workers Compensation Personal Injury1 | $12.3M | 2% |
| Health Care Management Service | $7.5M | 1% |
